1.2 OMIM# of the disease 301500.
1.3 Name of the analysed genes or DNA/chromosome segments Alpha-galactosidase A, GLA.
1.4 OMIM# of the gene(s) 300644.
Mutational spectrum
Disease-causing mutations are mostly point mutations (B70%) spread over the seven exons, about 28% smaller rearrangements affecting o60 nucleotides, and about 2% larger rearrangements affecting Z60 nucleotides. 1
Analytical methods
Bidirectional sequencing of all coding exons and short adjacent intronic sequences.
Analytical validation
Bidirectional sequencing; control of results by parallel use of alternative molecular genetic methods (eg, restriction analysis, ASO-PCR and so on); analysis of samples of family members (as positive and negative controls); comparison with data base entries and data in the literature; quality control through sharing samples.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1 per 30 000-35 000 births.
1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting

Comment:
A large proportion (figures vary largely from author to author, based on unpublished data of the authors: up to 80%) of female carriers manifests disease-specific clinical features, which may be similar in severity to the symptoms of male patients (this is in contrast to the majority of X-linked metabolic diseases), although usually at a later age than male patients. 2 Nevertheless, in females, a reliable diagnosis can only be made by gene analysis.
TEST CHARACTERISTICS
Analytical sensitivity (proportion of positive tests if the genotype is present)
In case of bidirectional sequencing of all coding exons and short adjacent intronic sequences, B98% in males and B96% in females (unpublished data of the authors).
2.2 Analytical specificity (proportion of negative tests if the genotype is not present) Not appropriate.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors, such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Practically 100%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
In case of known disease-causing mutations, almost 100% of males and up to 80% of females develop signs and/or symptoms of the disease (unpublished data of the authors), whereas expressivity is very variable both within the same family and among different families carrying the same mutation.
2.6 Negative clinical predictive value (probability not to develop the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Practically 100% Index case in that family had not been tested:
Depending on age and degree of relationship, B98% in males and B96% in females if bidirectional sequencing of all coding exons and short adjacent intronic sequences was performed (unpublished data of the authors). In case of potential heterozygotes, the knowledge of not having an elevated carrier risk results in 'relief' with regard to the familial risk, and allows an informed decision on family planning and prenatal diagnosis.
CLINICAL UTILITY
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
At present, enzyme replacement therapy (ERT) with a-galactosidase A is the only option to prevent disease progression and serious organ damage. Since life expectancy of untreated patients is significantly reduced both in males and in females, regular monitoring and timely diagnosis of disease-specific signs and symptoms are essential. The major causes of morbidity and mortality are renal failure, cardiovascular disease, and stroke. Therefore, management of patients with Fabry disease requires a multidisciplinary team of medical sub-specialists.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked)
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? Yes, X-linked inheritance is proven.
Can a genetic test in the index patient save genetic or other tests in family members?
Yes. Knowing the disease-causing mutation allows specific analysis of the proband's mutation in relatives whose health problems could not be assigned yet to a medical entity. 
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